Technologies for a better tomorrow
Fundamental and applied research. Tech discovery. Top-tier scientific publications. Innovative patents.
Research
Advancing generative and agentic AI with NEC’s AI Harness to deliver transparent and controlled, enterprise-grade AI productivity.
Accelerating applied AI technology research for cross-industry digitization and transformation.
Developing new technology for the improved health and well-being of humanity, including cancer therapies and digital health solutions. Advancing scientific computing to accelerate discovery, enable simulations, and solve complex real-world challenges.
Enabling next‑generation non‑terrestrial networks through 5G technologies, integrated seamlessly into space.
Case studies
About us
In finding new ways to push the boundaries of science, we deliver technology that significantly benefits the environment, society and our lives.
Our researchers choose their own projects, lead scientific discovery and regularly present their results at top, peer-reviewed scientific conferences. We are committed to open-innovation technology that benefits science and society.
NEC Laboratories Europe is a world pioneer in advancing and applying graph-based relational learning. Our GraphAI technology discovers and exploits relations between data entities, eliminating the problem of missing data points and linking multimodal data.
Governments and scientists are in a race against time to identify and control the spread of emerging viruses before they become pandemics. NEC Laboratories Europe is currently working with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccines effective against SARS-CoV-2 variants and other betacoronaviruses.
Neoantigens can be used to develop personalized therapeutic cancer vaccines that teach the patient's immune system to recognize and kill cancer cells. The NEC Neoantigen Prediction Pipeline uses bioinformatics and machine learning to analyze the DNA and RNA of cancer patients to identify neoantigens originating from cancer mutations. NEC Laboratories Europe was a key contributor in developing the prediction pipeline, which enables NEC biotech partners to advance immunotherapy.
